{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:05:03Z","timestamp":1793855103076,"version":"4.6.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xphs.2026.104240","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:56:45Z","timestamp":1772841405000},"page":"104240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Artificial intelligence in pharmaceutical manufacturing: Applications, case studies, and GxP implementation considerations"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7591-1007","authenticated-orcid":false,"given":"Gowtham","family":"Nakka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katti Kartik","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2026.104240_bib0001","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/pharmaceutics17050623","article-title":"Aspects and implementation of pharmaceutical quality by design from conceptual frameworks to industrial applications","volume":"17","author":"Yang","year":"2025","journal-title":"Pharmaceutics"},{"issue":"120554","key":"10.1016\/j.xphs.2026.104240_bib0002","article-title":"Industry 4.0 for pharmaceutical manufacturing: preparing for the smart factories of the future","volume":"602","author":"Arden","year":"2021","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2026.104240_bib0003","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/pr8091088","article-title":"Digital twins in pharmaceutical and biopharmaceutical manufacturing: a literature review","volume":"8","author":"Chen","year":"2020","journal-title":"Processes"},{"key":"10.1016\/j.xphs.2026.104240_bib0004","series-title":"Discussion Paper: Artificial Intelligence in Drug Manufacturing","year":"2023"},{"issue":"3","key":"10.1016\/j.xphs.2026.104240_bib0005","doi-asserted-by":"crossref","first-page":"945","DOI":"10.53730\/ijhs.v9n3.15834","article-title":"Artificial intelligence in pharmaceutical manufacturing: transforming sterile compounding and quality assurance","volume":"9","author":"Nakka","year":"2025","journal-title":"Int J Health Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104240_bib0006","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/pharmaceutics13060919","article-title":"Process analytical technology tools for monitoring pharmaceutical unit operations: a control strategy for continuous process verification","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"issue":"125322","key":"10.1016\/j.xphs.2026.104240_bib0007","article-title":"Data-driven model predictive control for continuous pharmaceutical manufacturing","volume":"672","author":"Vega-Zambrano","year":"2025","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104240_bib0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/data10120201","article-title":"Data quality in the age of AI: a review of governance, ethics, and the FAIR principles","volume":"10","author":"Guillen-Aguinaga","year":"2025","journal-title":"Data"},{"issue":"125957","key":"10.1016\/j.xphs.2026.104240_bib0009","article-title":"Trends and new process analytical technologies in pharmaceutical manufacturing","volume":"682","author":"Wu","year":"2025","journal-title":"Int J Pharm"},{"issue":"100263","key":"10.1016\/j.xphs.2026.104240_bib0010","article-title":"Digitization in bioprocessing: the role of soft sensors in monitoring and control of downstream processing for production of biotherapeutic products","volume":"12","author":"Rathore","year":"2022","journal-title":"Biosens Bioelectron X"},{"issue":"4","key":"10.1016\/j.xphs.2026.104240_bib0011","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tibtech.2022.08.007","article-title":"Artificial intelligence and machine learning applications in biopharmaceutical manufacturing","volume":"41","author":"Rathore","year":"2023","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.xphs.2026.104240_bib0012","unstructured":"U.S. Food and Drug Administration. Inspection of injectable products for visible particulates: draft guidance for industry. December 2021. (accessed March 13, 2026)."},{"issue":"1","key":"10.1016\/j.xphs.2026.104240_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5731\/pdajpst.2024-003017.1","article-title":"Visual inspection of topical ophthalmic formulations packaged in opaque and semi-transparent containers: working towards alignment with USP Visible Particulates in injections","volume":"79","author":"Ciolkowski","year":"2025","journal-title":"PDA J Pharm Sci Technol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104240_bib0014","first-page":"376","article-title":"Applying machine learning to the visual inspection of filled injectable drug products","volume":"77","author":"Veillon","year":"2023","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.xphs.2026.104240_bib0015","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). MHRA GXP data integrity guidance and definitions. Revision 1. March 2018. (accessed March 13, 2026)."},{"key":"10.1016\/j.xphs.2026.104240_bib0016","doi-asserted-by":"crossref","unstructured":"National Institute of Standards and Technology. Artificial intelligence risk management framework (AI RMF 1.0). NIST AI 100-1. January 2023. https:\/\/doi.org\/10.6028\/NIST.AI.100-1. (accessed March 13, 2026).","DOI":"10.6028\/NIST.AI.100-1"},{"issue":"120624","key":"10.1016\/j.xphs.2026.104240_bib0017","article-title":"Soft sensor for real-time estimation of tablet potency in continuous direct compression manufacturing operation","volume":"602","author":"Kamyar","year":"2021","journal-title":"Int J Pharm"},{"issue":"120620","key":"10.1016\/j.xphs.2026.104240_bib0018","article-title":"A hybrid NIR-soft sensor method for real time in-process control during continuous direct compression manufacturing operations","volume":"602","author":"Cogoni","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104240_bib0019","unstructured":"U.S. Food and Drug Administration. PAT\u2014A framework for innovative pharmaceutical development, manufacturing, and quality assurance. September 2004. (accessed March 13, 2026)."},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104240_bib0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijpharm.2017.05.075","article-title":"Multivariate statistical process control of a continuous pharmaceutical twin-screw granulation and fluid bed drying process","volume":"528","author":"Silva","year":"2017","journal-title":"Int J Pharm"},{"issue":"463486","key":"10.1016\/j.xphs.2026.104240_bib0021","article-title":"Application of advanced machine learning algorithms for anomaly detection and quantitative prediction in protein A chromatography","volume":"1682","author":"Tiwari","year":"2022","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.xphs.2026.104240_bib0022","unstructured":"International Conference on Harmonisation. Pharmaceutical quality system Q10. Current Step 4 version. June 4, 2008. (accessed March 13, 2026)."},{"issue":"9","key":"10.1016\/j.xphs.2026.104240_bib0023","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/pharmaceutics17091121","article-title":"Science-based risk assessment for the categorization of visual inspection defects of sterile dosage forms","volume":"17","author":"Mahler","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2026.104240_bib0024","doi-asserted-by":"crossref","unstructured":"United States Pharmacopeia. General chapter <1790> visual inspection of injections. In: USP\u2013NF. Rockville, MD: United States Pharmacopeia; 2023. https:\/\/doi.org\/10.31003\/USPNF_M7198_06_01. (accessed March 13, 2026).","DOI":"10.31003\/USPNF_M7198_06_01"},{"key":"10.1016\/j.xphs.2026.104240_bib0025","series-title":"Inspection of Injectable Products for Visible Particulates","year":"2021"},{"issue":"5","key":"10.1016\/j.xphs.2026.104240_bib0026","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/bit.28943","article-title":"Machine learning-powered optimization of a CHO cell cultivation process","volume":"122","author":"Richter","year":"2025","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.xphs.2026.104240_bib0027","series-title":"Data Integrity and Compliance with Drug CGMP: Questions and Answers","year":"2022"},{"issue":"6","key":"10.1016\/j.xphs.2026.104240_bib0028","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3390\/ph18060901","article-title":"Regulatory perspectives for AI\/ML implementation in pharmaceutical GMP environments","volume":"18","author":"Niazi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xphs.2026.104240_bib0029","unstructured":"Center for Drug Evaluation, Research. Q10 Pharmaceutical Quality system. U.S. Food and Drug Administration. May 15, 2020. Accessed January 4, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/q10-pharmaceutical-quality-system"},{"key":"10.1016\/j.xphs.2026.104240_bib0030","series-title":"Q9(R1) Quality Risk Management","year":"2023"},{"key":"10.1016\/j.xphs.2026.104240_bib0031","series-title":"ICH Q12: Implementation Considerations for FDA-Regulated Products","year":"2021"},{"issue":"4","key":"10.1016\/j.xphs.2026.104240_bib0032","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s43441-023-00530-4","article-title":"Validation of artificial intelligence containing products across the regulated healthcare industries","volume":"57","author":"Higgins","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.xphs.2026.104240_bib0033","unstructured":"World Health Organization. Guideline on data integrity. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fifth report. WHO Technical Report Series, No. 1033. Geneva, Switzerland: World Health Organization; 2021:136-155. (accessed March 13, 2026)."},{"key":"10.1016\/j.xphs.2026.104240_bib0034","series-title":"Guidance for Industry q10 Pharmaceutical Quality System","year":"2009"},{"key":"10.1016\/j.xphs.2026.104240_bib0035","series-title":"Process Validation: General Principles and Practices","year":"2020"},{"issue":"2","key":"10.1016\/j.xphs.2026.104240_bib0036","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.62110\/sciencein.btl.2025.v12.1161","article-title":"Beyond Ethylene oxide (EtO): a comprehensive review of sustainable sterilization technologies for medical devices","volume":"12","author":"Pereira","year":"2025","journal-title":"Biomed Ther Lett"},{"key":"10.1016\/j.xphs.2026.104240_bib0037","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2020.06.002","article-title":"Deep learning for continuous manufacturing of pharmaceutical solid dosage form","volume":"153","author":"Roggo","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2026.104240_bib0038","doi-asserted-by":"crossref","first-page":"115764","DOI":"10.1016\/j.addr.2025.115764","article-title":"Quality by computational design. harnessing AI to advance rational drug development","volume":"229","author":"Wang","year":"2026","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:23:19Z","timestamp":1776446599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0022354926000894"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104240","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence in pharmaceutical manufacturing: Applications, case studies, and GxP implementation considerations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104240"}}